Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$1.1BCash on Hand
128.7mo Cash Runway
Follow PBLS by emailGet an email when PBLS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PBLS, unsubscribe in one click. Privacy
📣 What PBLS Says Is Next
first quarter of 2027 · “Anticipate disclosing additional clinical data in HCC at a medical meeting in the first quarter of 2027, building on evidence of early activity in a heavily pretreated patient”
Company press release, Nov 12, 2026 · SEC filing
first half of 2027 · “Anticipate disclosing updated clinical data from additional patients with ACP in the first half of 2027, building on encouraging early antitumor activity in three patients Hepatocellular carcinoma and additional Wnt/β-catenin-driven tumors”
Company press release, Nov 12, 2026 · SEC filing
first quarter of 2027 · “Anticipate disclosing clinical data from additional patients with FAP in the first quarter of 2027, building on compelling early observations of duodenal polyp reductions in two patients Adamantinomatous craniopharyngioma”
Company press release, Nov 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Earnings Reported Q3 2026 results: $1.1 billion in cash, expected to fund operations into 2030, with Q3 net loss of $44.5 million versus $33.5 million a year earlier. Form 8-K · SEC filing · Press release
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 5, 2026 ·
Deal Parabilis Medicines amended its Cambridge, Massachusetts headquarters lease on October 30, 2026. The amendment adds 33,525 square feet at 20 Acorn Park Drive from January 1, 2028, extends the term to December 31, 2037, and abates eight months of base rent. Form 8-K · SEC filing
Sep 15, 2026 ·
Clinical trial Parabilis plans an oral presentation of updated clinical data from its Phase 1/2 study of zolucatetide in desmoid tumor patients at the ESMO Congress 2026 in Madrid, scheduled for Saturday, October 24 at 2:45pm CEST (8:45am ET). Form 8-K · SEC filing
Sep 2, 2026 ·
Leadership Chief Medical Officer Fawzi Benzaghou, M.D., will transition out of the company effective September 30, 2026, following a mutual agreement reached August 28, 2026. He will receive severance under his employment agreement. Form 8-K · SEC filing
Aug 25, 2026 ·
Leadership Board increased to nine directors and appointed Craig Tendler, M.D., as a Class II director and Science & Technology Committee member, with a 20,294-share option at $39.36 and standard non-employee director pay. Dr. Tendler previously led oncology clinical development and medical affairs at Johnson & Johnson. Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Earnings Reported Q2 2026 results: cash, equivalents and marketable securities of $1.1B, funding operations into 2030. Net loss was $52.5M versus $34.8M a year earlier, with R&D expenses of $39.4M. Regeneron collaboration brought $125M in upfront consideration and equity, with up to $2.2B in milestones. Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Apr 2027 · Phase 1/2 · Recruiting · FOG-001 in Locally Advanced or Metastatic Solid Tumors Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not PBLS's own candidates): Bevacizumab, Nivolumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
PBLS holds $1.1B in cash and short-term investments (as of Jun 30, 2026) and burns about $26.1M/quarter from operations,
an estimated runway of 128.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:0 · Low
Cash runway 129 months
S-1 registration (May 2026) +8
Company says cash lasts into 2030 -15We believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements into 2030.10-Q, Nov 2026
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PBLS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.